Bictegravir

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Bictegravir is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2018. DrugCentral lists 3 molecular targets, including pol, Integrase and SLC22A2. Recorded indications include Human immunodeficiency virus infection.

• Approval status: onp (first approved 2018 by the FDA).
• Molecular targets: pol, Integrase and SLC22A2 (3 listed in DrugCentral).
• Indications: Human immunodeficiency virus infection.
• ATC code: J05AR20 (Antivirals for treatment of HIV infections, combinations).
• Molecular formula: C21H18F3N3O5; molecular weight 449.39 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Human immunodeficiency virus infection

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Integrase	pol	inhibitor	IC50 8.12
Integrase	—	unknown	IC50 8.12
Solute carrier family 22 member 2	SLC22A2	unknown	IC50 6.31

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2019-03-26	PMDA	—	Gilead Sciences K.K.	Yes
2018-06-21	EMA	—	Gilead Sciences International Limited
2018-02-07	FDA	—	GILEAD SCIENCES INC

ATC classification

ATC code	Therapeutic hierarchy
J05AR20	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Viral mutation identified	82.5
Pathogen resistance	61.4
Viral load increased	58.8
Drug resistance	58.1
Virologic failure	48.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Bictegravir is on its molecule page.

• Molecular formula: C₂₁H₁₈F₃N₃O₅
• Molecular weight: 449.39 g/mol
• CAS number: 1611493-60-7
• InChIKey: SOLUWJRYJLAZCX-LYOVBCGYSA-N
• PubChem CID: 90311989

OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC2=C(F)C=C(F)C=C2F)C1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Bictegravir used for?

DrugCentral lists the following indications for Bictegravir: Human immunodeficiency virus infection.

How does Bictegravir work?

Its molecular targets in DrugCentral include pol (inhibitor), Integrase and SLC22A2.

When was Bictegravir first approved?

Bictegravir was first approved by the FDA in 2018.

What is the chemical formula of Bictegravir?

Bictegravir has the molecular formula C21H18F3N3O5 and a molecular weight of 449.39 g/mol.

Sources

• DrugCentral drug card 5274 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3989866 — compound record and bioactivity
• PubChem CID 90311989 — chemical identifiers
• DrugBank DB11799 — drug record
• FDA UNII 8GB79LOJ07 — substance identity
• DailyMed: FDA labels for Bictegravir — current prescribing information (label search)
• UniProt O15244 (SLC22A2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.